Company News
T-MAXIMUM Receives FDA Clearance for MT027
FDA cleared T-MAXIMUM to start a Phase 2 trial of its B7‑H3 CAR‑T MT027 for brain metastases from lung and breast cancer.
It is MT027's second FDA‑cleared Phase 2 program, the first targeting recurren
